Pepticom

Novel Peptide Drug Candidates

Health Tech & Life Sciences
Active
Series A Jerusalem, Israel Founded 2011
Last updated 2026-06-18
Total raised
$14.2M
Last: 2025-01
Stage
Series A
Founded
2011
Headcount
15
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

Pepticom is a biotechnology company using artificial intelligence to streamline peptide drug discovery. Its algorithmic platform combines principles from economic and molecular mechanics to generate a wide scope of active molecules with higher success rates. In this way, Pepticom aims to lower the number of research and development candidates synthesized and tested, with a similar reduction in time and costs compared to traditional lab-based discovery methods. The use of computational technology allows Pepticom to address complex targets unreachable by laboratory methods and to further enhance research and development. The platform utilizes the structure of the target protein to design innovative peptides at atomic resolution. It is also capable of designing several peptides chemistry, including linear, helical, and cyclic peptides, and incorporating D and non-natural amino acids in the process. The company is involved in various successful discovery projects with academic and industry partners and has several molecules in different development stages. In March 2021, Pepticom established a spin-off company, PeptiCov, which will focus on developing treatments for the SARS-CoV-2 virus responsible for the COVID-19 outbreak.

Funding history · 4 rounds · $14.2M total

2025-01
2021-03
2013-08
Undisclosed

Q&A

What is Pepticom's primary focus?
Pepticom is a biotechnology company that uses artificial intelligence to streamline peptide drug discovery, aiming to generate novel peptide drug candidates with higher success rates.
When was Pepticom founded?
Pepticom was founded in December 2011.
What is Pepticom's total funding to date?
Pepticom has raised a total of $14.2 million USD across multiple funding rounds.
When did Pepticom complete its most recent funding round and who invested?
In January 2025, Pepticom completed a funding round of $6.6 million USD, with investment from The Chartered Group.
Did Pepticom establish any spin-off companies?
Yes, in March 2021, Pepticom established PeptiCov, a spin-off company focused on developing treatments for the SARS-CoV-2 virus.
Who are the co-founders of Pepticom?
The co-founders of Pepticom are Immanuel Lerner, Anwar Rayan, and Amit Michaeli.
What is Pepticom's primary sector?
Pepticom's primary sector is Health Tech & Life Sciences, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.

Team · 3

Founder · CEO, Co-Founder & Director
LinkedIn ↗
Founder · Co-Founder
LinkedIn ↗
Founder · Co-founder & CTO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B

Highlights

1 PatentsVerified

Tags

bioinformaticsdrug-discoveryimmunologybiotechnologyoncologyanalysis-softwareartificial-intelligenceagriculturepharma-companiespharmaceuticalsmetabolic-diseasebiopharmaceuticalcancerpeptides
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)